source
- Roche signs $100 million upfront deal with Alector to advance Parkinson's researchRoche announced a partnership with biotech Alector focused on neuroscience and Parkinson's disease, providing an upfront cash payment of $100 million. The agreement aims to combine Roche's resourc…
- Vaxcyte’s pneumococcal vaccine meets primary goals in Phase 3 trial, challenging Pfizer and MerckVaxcyte announced that its experimental pneumococcal vaccine, VAX-31, achieved the primary endpoints in a pivotal Phase 3 study. The data, presented in a company release, show the shot met its pred…